EHA 2024 | CAPTIVATE trial: 5.5yr follow-up of the fixed-duration cohort
Ryan Jacobs
• 16 Jun 2024
Ryan Jacobs, MD, Atrium Health Levine Cancer Institute, Charlotte, NC, presents the results from the 5.5-year follow-up of the fixed-duration cohort of the Phase II CAPTIVATE study (NCT02910583), which evaluates the safety and efficacy of ibrutinib in combination with venetoclax in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Dr Jacobs highlights that the efficacy data continue to be encouraging across all risk categories. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
